文献速递乳腺外科

激素受体阳性淋巴结阴性乳腺癌局部区域复发的种族差异:TAILORx试验事后分析

Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2023-01-01

该事后分析纳入TAILORx随机试验中9369例T1-2N0激素受体阳性HER2阴性乳腺癌患者,评估局部区域复发(LRR)的种族差异。调整后亚裔(HR 1.91)和黑人(HR 1.78)与LRR独立相关,LRR与乳腺癌死亡风险升高独立相关(HR 5.71)。

要点

  • 亚裔和黑人乳腺癌患者局部区域复发风险高于白人。
  • LRR与乳腺癌死亡风险升高独立相关。
  • 需探究LRR后救治失败是否导致死亡差异。

核心结论

  • 在TAILORx试验人群中,尽管治疗接受率高,亚裔和黑人患者的LRR率仍高于白人。
  • LRR与乳腺癌死亡风险升高独立相关。

研究设计与样本

  • TAILORx随机临床试验的未计划回顾性事后分析,2006至2010年入组,随访9年。
  • 纳入9369例T1-2N0激素受体阳性ERBB2阴性乳腺癌女性,排除种族未知或失访者。

主要发现

  • 调整患者、肿瘤和治疗因素后,亚裔(HR 1.91,95%CI 1.12-3.29)和黑人(HR 1.78,95%CI 1.15-2.77)与LRR独立相关。
  • 调整后LRR与乳腺癌死亡风险升高独立相关(HR 5.71,95%CI 3.50-9.31)。

关键数值与推荐

  • LRR定义为同侧乳腺、皮肤、胸壁或区域淋巴结复发,不伴同时远处转移。
  • 治疗分配依据Oncotype DX复发评分:<11仅内分泌治疗,11-25内分泌治疗对比化疗后内分泌治疗,>25化疗后内分泌治疗。
  • 内分泌治疗中位持续时间超过60个月,各族裔组范围61.1至65.9个月;72.6%患者接受放疗。

临床怎么用

  • 对外科医生而言,应关注亚裔和黑人HR阳性淋巴结阴性乳腺癌患者的局部区域复发风险。
  • 尽管试验内治疗接受率高,LRR种族差异仍存在,提示需探究LRR后救治差异。

局限性

  • 为未计划的事后分析,可能存在残余混杂。
  • 排除种族未知或失访患者可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether racial and ethnic disparities in locoregional recurrence (LRR) exist among patients with similar access to care treated in randomized clinical trials is unknown. OBJECTIVE: To examine racial and ethnic differences in LRR among patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (ERBB2 [formerly HER2 or HER2/neu])-negative, node-negative breast cancer enrolled in the Trial Assigning Individualized Options for Treatment (TAILORx). DESIGN, SETTING, AND PARTICIPANTS: This unplanned retrospective post hoc analysis examined a prospective multicenter clinical trial population of women with breast cancer enrolled between 2006 and 2010, with 9 years of follow-up. The TAILORx investigators randomized patients to treatment based on their Oncotype DX recurrence score, including endocrine therapy alone (recurrence score <11), endocrine therapy alone vs chemotherapy followed by endocrine therapy (recurrence score 11-25), or chemotherapy followed by endocrine therapy (recurrence score >25). Patients with unknown race and ethnicity or lack of follow-up were excluded from this analysis. Data analysis was performed between December 2021 and March 2022. MAIN OUTCOME AND MEASURES: Locoregional recurrence was defined as ipsilateral in breast, skin, chest wall, or regional nodal recurrence without concurrent distant recurrence, and was stratified by racial and ethnic group. Unadjusted Kaplan-Meier and adjusted Cox proportional hazards regression models were used for survival analyses. RESULTS: Of the 10 273 women enrolled in TAILORx, this analysis included 9369 with T1-2N0 HR-positive, ERBB2-negative breast cancer. Of these patients, 428 (4.6%) were Asian, 886 (9.4%) were Hispanic, 676 (7.2%) were non-Hispanic Black (hereinafter Black), and 7406 (78.8%) were non-Hispanic White (hereinafter White). Assigned treatment receipt was high, with a 9.3% (n = 870) crossover of treatment groups and a median endocrine therapy duration of longer than 60 months, ranging from 61.1 to 65.9 months, across racial and ethnic groups. A total of 6818 patients (72.6%) received radiation (6474 [96.1%] after breast-conserving surgery and 344 [13.0%] after mastectomy). At a median follow-up of 94.8 months (range, 1-138 months), 8-year LRR rates were 3.6% (95% CI, 1.6%-5.6%) in Asian patients, 3.9% (95% CI, 2.2%-5.4%) in Black patients, 3.1% in Hispanic patients (95% CI, 1.7%-4.5%), and 1.8% (95% CI, 1.5%-2.3%) in White patients (P < .001). In survival analyses adjusted for patient, tumor, and treatment factors, Asian race (hazard ratio, 1.91 [95% CI, 1.12-3.29]) and Black race (1.78 [1.15-2.77]) were independently associated with LRR. In adjusted survival analyses for breast cancer mortality, LRR was independently associated with increased breast cancer mortality (hazard ratio, 5.71 [95% CI, 3.50-9.31]). CONCLUSIONS AND RELEVANCE: In this post hoc analysis, racial and ethnic differences in LRR were observed among patients with T1-2N0 HR-positive, ERBB2-negative breast cancer despite high rates of treatment receipt in this clinical trial population, with the highest LRR rates in Asian and Black patients. Further study is needed to understand whether failure to rescue after LRR may contribute to racial disparities in breast cancer mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00310180.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Kantor O, King TA, Freedman RA, et al. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. JAMA Surg. 2023. PMID: 37043210. doi:10.1001/jamasurg.2023.0297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。